WuXi AppTec reported a 33.7 per cent rise in H1 net profit to 11.08 billion yuan, beating expectations driven by strong demand for weight-loss and diabetes drugs and US growth.
Wuxi AppTec, Asia's largest contract pharmaceutical research provider, reported H1 net income of 11.08 billion yuan, surpassing market estimates. This strong performance was driven by robust demand for weight-loss and diabetes drugs, alongside significant growth in its US business.
WuXi AppTec's Hong Kong-traded stock jumped 37% as major shareholders JPMorgan Chase, UBS Group, and BlackRock increased their stakes. The company is set to release its half-year earnings on August 3, with high market expectations.
China sanciona 46 empresas americanas e suspende exportações de itens de dupla utilização para produtoras de terras raras e fabricantes de motores, em resposta a lista do Pentágono que inclui companhias chinesas ligadas a atividades militares.
China suspendeu exportações de itens de dupla utilização para empresas americanas como MP Materials e Aveox, citando práticas maliciosas dos EUA. Em resposta, sanções foram impostas a 46 outras empresas americanas, impedindo compradores chineses de adquirir seus produtos.
The US Department of Defense added WuXi AppTec to its list of Chinese military companies. Analysts predict minimal impact on the company and the broader pharma sector due to cost efficiencies and ongoing collaboration.
WuXi AppTec reported record Q1 revenue of 12.44 billion yuan (US$1.72 billion), up 28.81% year-on-year, beating market expectations of 10.78 billion yuan. Net profit rose nearly 27% to 4.65 billion yuan, exceeding forecasts of 3.9 billion yuan. The pharmaceutical contract manufacturer has a record order backlog of 59.77 billion yuan, up 23.6% from a year earlier.
